Mistletoe therapy is gaining increasing attention in integrative cancer care for its immune-modulating and quality-of-life-enhancing properties. As a plant-based extract derived from Viscum album, its therapeutic use requires a carefully monitored dosage plan — one that is tailored to each patient.
At ABNOBA GmbH, we emphasize that mistletoe treatment is not about high doses but about personalized, gradual adjustment. The goal is to stimulate the immune system without overwhelming it. Treatment typically starts with a very low dose, often around 0.01 mg, to observe how the body reacts.
In the following weeks, doses may be increased slowly, depending on the individual’s tolerance, response, and clinical goals. Factors such as the type and stage of cancer, ongoing therapies (like chemotherapy or radiation), and the patient’s overall condition are all considered in dose planning.
Mistletoe extracts are injected under the skin, commonly 2–3 times a week. Patients are monitored for local skin reactions or mild flu-like symptoms — signs that the immune system is responding. Over time, many patients transition to home administration with medical guidance.
ABNOBA’s mistletoe products come from different host trees (like fir, apple, pine), each offering a unique therapeutic profile and requiring specific dosage schemes.
It’s vital to note: there is no universal dosage. Mistletoe therapy must be administered under the care of a trained physician familiar with integrative oncology protocols.
For expert advice or to begin your journey with mistletoe therapy, connect with ABNOBA India.
